Moderna
MRNA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 2 days ago • MRNA
Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript
Zacks Investment Research • 2 days ago • MRNA
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
Proactive Investors • 2 days ago • MRNA
Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings
Seeking Alpha • 2 days ago • MRNA
Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook
Zacks Investment Research • 2 days ago • MRNA
Moderna (MRNA) Reports Q1 Loss, Beats Revenue Estimates
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.